Study population
Subjects were Japanese males aged between 20 and 46 years, with a body
mass index between ≥ 18.5 and < 25.0 kg m-2
-1. Eligible subjects had no clinically problematic abnormalities
regarding their medical findings, vital signs, electrocardiogram, and
laboratory tests, and the investigator determined that there were no
problems that would have prevented participation in this study. The
following subjects were excluded: those who had a previous or current
history of functional disorders related to the liver, heart, kidney,
lungs, blood, gastrointestinal tract, or any other disorders that would
preclude their participation; a previous or current history of upper
gastrointestinal disorders; a history of drug allergy; white blood cell
count ≤ 4000 µL-1; neurological symptoms; a previous
or current history of serious infectious diseases, including
opportunistic infections within 1 year prior to administration of the
study drug; ingestion of grapefruit, grapefruit juice or foods
containing these ingredients within 8 days prior to the start of
administration of the study drug; or ingestion of St. John’s Wort or
foods containing these ingredients within 15 days prior to the start of
administration of the study drug.